Salivary, lacrimal and nasal (SALANS) measure to assess side effects following radioactive iodine treatment: development, psychometric properties, and factor structure-Reference-Cited by-同舟云学术

Salivary, lacrimal and nasal (SALANS) measure to assess side effects following radioactive iodine treatment: development, psychometric properties, and factor structure

Published:2024-05-20 Issue:7 Volume:33 Page:2011-2023
ISSN:0962-9343
Container-title:Quality of Life Research
language:en
Short-container-title:Qual Life Res

Author:

Jonklaas Jacqueline^ORCID,Carr Alaina L.^ORCID,Luta George^ORCID,Yu Chenlu,Jensen Roxanne E.^ORCID,Reasner Emma^ORCID,Winslow Justin^ORCID,Kuo Charlene C.^ORCID,Davidson Bruce J.,Esposito Giuseppe^ORCID,Bloom Gary^ORCID,Diamond-Rossi Samantha A.^ORCID,Graves Kristi D.^ORCID

Funder

National Institute of Dental and Craniofacial Research

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11136-024-03684-2.pdf

Reference46 articles.

1. Fard-Esfahani, A., Emami-Ardekani, A., Fallahi, B., Fard-Esfahani, P., Beiki, D., Hassanzadeh-Rad, A., & Eftekhari, M. (2014). Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nuclear Medicine Communications, 35(8), 808–817. https://doi.org/10.1097/MNM.0000000000000132

2. Duan, H., Gamper, E., Becherer, A., & Hoffmann, M. (2015). Quality of life aspects in the management of thyroid cancer. Oral Oncology, 51(6), S1-5. https://doi.org/10.1016/j.oraloncology.2015.03.008

3. Institute of Medicine & National Research Council. (2006). From Cancer Patient to Cancer Survivor: Lost in Transition. The National Academies Press. https://doi.org/10.17226/11468

4. Levit, L. A., Balogh, E., Nass, S. J., & Ganz, P. (2013). Delivering high-quality cancer care: Charting a new course for a system in crisis. National Academies Press Washington.

5. Caglar, M., Tuncel, M., & Alpar, R. (2002). Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clinical Nuclear Medicine, 27(11), 767–771.